November 11, 2026 12:52 PM

Cheaper cancer medicines: What the new 30% trade margin cap means for patients

Cancer treatment can place a substantial financial burden on patients and their families, particularly when the cost of medicines rises significantly between the manufacturer and the retail counter. To address this concern, the Centre has introduced a 30% cap on trade margins for 137 non-scheduled anti-cancer medicines, aiming to reduce the prices patients pay for these drugs. The National Pharmaceutical Pricing Authority (NPPA), through an order issued on October 17, 2026, brought the medicine...

November 9, 2026 4:45 PM

Revised MRPs of 1,364 anti-cancer formulations come into effect; consumers to save Rs 3,540 cr/year

Revised Maximum Retail Prices (MRPs) of 1,364 anti-cancer formulations have come into effect from Monday, a move projected to save consumers an estimated Rs 3,540.38 crore annually, according to an official release. The National Pharmaceutical Pricing Authority (NPPA), functioning under the Department of Pharmaceuticals, capped trade margins on the MRP of 137 anti-cancer drugs based on recommendations submitted on October 17, 2026, by an Expert Committee constituted by the Directorate General o...